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DOI 10.1186/s13148-015-0065-5RESEARCH Open AccessPhase I study of azacitidine and oxaliplatin in
patients with advanced cancers that have relapsed
or are refractory to any platinum therapy
Apostolia M Tsimberidou1*, Rabih Said1,2, Kirk Culotta3, Ignacio Wistuba4, Jaroslav Jelinek5, Siqing Fu1,
Gerald Falchook1, Aung Naing1, Sarina Piha-Paul1, Ralph Zinner1, Zahid H Siddik3, Guangan He3, Kenneth Hess6,
David J Stewart7, Razelle Kurzrock1,8 and Jean-Pierre J Issa5Abstract
Background: Demethylation process is necessary for the expression of various factors involved in chemotherapy
cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter
CTR1. We hypothesized that azacitidine and oxaliplatin combination therapy may restore platinum sensitivity. We
treated patients with cancer relapsed/refractory to any platinum compounds (3 + 3 study design) with azacitidine
(20 to 50 mg/m2/day intravenously (IV) over 15 to 30 min, D1 to 5) and oxaliplatin (15 to 30 mg/m2/day, IV over
2 h, D2 to 5) (maximum, six cycles). Platinum content, LINE1 methylation (surrogate of global DNA methylation),
and CTR1 expression changes (pre- vs. post-treatment) were assessed. Drug pharmacokinetics were analyzed.
Results: Thirty-seven patients were treated. No dose-limiting toxicity (DLT) was noted at the maximum dose. The
most common adverse events were anemia and fatigue. Two (5.4%) patients had stable disease and completed six
cycles of therapy. Oxaliplatin (D2) and azacitidine (D1 and 5) mean systemic exposure based on plasma AUCall showed
dose-dependent interaction whereby increasing the dose of oxaliplatin reduced the mean azacitidine exposure and
vice versa; however, no significant differences in other non-compartmental modeled parameters were observed. Blood
samples showed universal reduction in global DNA methylation. In tumor samples, hypomethylation was only
observed in four out of seven patients. No correlation between blood and tumor demethylation was seen. The
mean cytoplasmic CTR1 score decreased. The pre-dose tumor oxaliplatin levels ranged from <0.25 to 5.8 μg/g
tumor. The platinum concentration increased 3- to 18-fold. No correlation was found between CTR1 score and
oxaliplatin level, which was found to have a trend toward correlation with progression-free survival.
Conclusions: Oxaliplatin and azacitidine combination therapy was safe. CTR1 expression was not correlated with
methylation status or tissue platinum concentration.
Keywords: DNA methylation, Platinum resistance, Copper/platinum transporterBackground
Platinum compounds are known to have a wide range of
antitumor activity both clinically and pre-clinically [1].
However, certain tumors either are initially refractory to
platinum treatment or subsequently develop resistance.
For instance, oxaliplatin (a third-generation platinum
compound) is recommended as a frontline therapy for* Correspondence: atsimber@mdanderson.org
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unless otherwise stated.colorectal cancer (CRC), but patients eventually experi-
ence resistance to oxaliplatin followed by subsequent re-
lapse and death.
Resistance to platinum-based chemotherapy can be
caused by DNA hypermethylation, a critical epigenetic
process in cancer progression. The hypermethylation of
specific genes by DNA methyltransferase promotes
tumorigenesis [2-5] and chemotherapy resistance [6]. Al-
though many factors contribute to chemotherapy resist-
ance [7], flattening of the dose-response curve at higher
drug doses suggests that a deficiency of certain cell-ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cytotoxicity [8]. For instance, platinum-resistant cells
have been shown to have hypermethylation of the
MLH1 mismatch repair gene that is important in trig-
gering platinum cytotoxicity [9] or a pleiotropic reduc-
tion in transporters [10,11] that is potentially reversible
by a DNA methyltransferase inhibitor such as decita-
bine [12]. In fact, expression of the copper transporter
CTR1, a main contributor to cellular platinum uptake
[13], rapidly decreases once CTR1 is exposed to plat-
inum compounds, thereby reducing platinum influx
[12]. In addition, in a phase I clinical trial of the hypo-
methylating agent decitabine in patients with refractory
solid tumors and lymphomas, administration of decita-
bine significantly increased CTR1 expression [14].
Since the CpG island methylator phenotype was dis-
covered in 1999 [15], it has been extensively used in
assessing patients with CRC [16,17]. The role of de novo
methylation in cancer was validated by comparing colon
cancer tumor tissue with matched normal colon tissue;
the cancer cells were found to be dependent on DNA
methylation-mediated epigenetic silencing of selected
genes. These data suggested that driver epigenetic events
are associated with cancer cell survival and can repre-
sent potential targets for therapy [18]. As innovative
immunomodulation is being increasingly used in tar-
geted therapy, the role of hypomethylation in immuno-
modulation is also evolving. Several investigators have
demonstrated that DNA methylation plays a major role
in the expression of various cancer tissue antigens and
immunomodulatory checkpoints [19-21].
The hypomethylating agent azacitidine, a DNA meth-
yltransferase inhibitor compound approved for the treat-
ment of myelodysplastic syndrome, is known to have
two main mechanisms of antineoplastic activity: cytotox-
icity, resulting from its incorporation into RNA and DNA,
and DNA hypomethylation, restoring normal growth con-
trol and differentiation in hematopoietic cells. The induc-
tion of DNA hypomethylation appears to require lower
doses of azacitidine than does cytotoxicity [22] and may
modulate the resistance mechanisms in patients with
platinum-refractory advanced solid tumors; in fact, azaciti-
dine was shown to enhance the sensitivity of platinum-
resistant ovarian cancer cells to carboplatin [23].
We hypothesized that azacitidine would restore sensi-
tivity to oxaliplatin in patients with platinum-refractory/
resistant cancer. Oxaliplatin, which is comprised of an
organoplatinum complex in which the platinum atom is
complexed with the 1,2-diaminocyclohexane carrier lig-
and and with an oxalate ligand [24,25], has a different
spectrum of activity and low cross-resistance with cis-
platin [26]; a favorable toxicity profile, including minimal
renal and auditory toxicity [25,27]; and clinical antitu-
mor activity in a broad spectrum of tumor types. Theselection of oxaliplatin was also based on the Food and
Drug Administration-approved indications of this drug
in advanced CRC and on empirical data demonstrating
its antitumor activity in breast cancer, advanced carcin-
oma of the stomach, esophageal cancer, germ cell tumor,
non-Hodgkin’s lymphoma, non-small cell lung cancer,
and ovarian cancer.
The primary objectives of this phase I study were (a)
to determine the maximum tolerated dose of an azaciti-
dine and oxaliplatin combination regimen in patients
with advanced solid tumors or lymphomas relapsed or
refractory to any platinum compound and (b) to define
the pharmacokinetics of azacitidine and oxaliplatin. The
secondary objectives were for patients treated in the ex-
pansion phase of this study: (a) to assess the CTR1
score; (b) to assess changes in global DNA methylation;
(c) to measure changes in oxaliplatin levels in tumor bi-
opsy samples taken before and after the first cycle of
azacitidine plus oxaliplatin therapy; and (d) to correlate
results of the pharmacokinetic studies of azacitidine and
oxaliplatin with changes in CTR1, changes in global
DNA methylation, and changes in oxaliplatin levels in
tissue biopsies of patients treated in the expansion phase
of this study.
Results
Patients
A total of 41 patients were screened and 37 patients were
treated. Two patients did not meet the study inclusion cri-
teria, and two patients did not receive the study treatment
because of consent withdrawal and rapidly worsening per-
formance status, respectively. Patients’ baseline character-
istics are shown in Table 1. The most common tumor
type was CRC (62%), and the median number of prior sys-
temic therapies was 4 (range, 1 to 10). The median time
between prior platinum treatment and the first day on
trial was 4.9 months (range, 0.7 to 56). The median num-
ber of cycles received was 2 (range, 1 to 6). Two patients
received the maximum of six cycles. The remaining pa-
tients discontinued treatment because of disease progres-
sion (n = 35). The study was terminated early because of
limited funding for tumor biopsies following the recom-
mendation of The Cancer Therapy Evaluation Program.
Therefore, only 7 of 16 patients enrolled in the expansion
phase had tumor biopsies.
Dose escalation and expansion phase
Three patients were treated at each dose level (1 to 5),
and no dose-limiting toxicity (DLT) was noted (Table 2).
At dose level 6, the maximum level tested, six patients
were enrolled and no DLT was reported. Therefore, dose
level 6 was used in the expansion phase. Sixteen patients
were treated in the expansion phase. Overall, 22 patients
were treated at the maximum dose level tested.
Table 1 Patient baseline characteristics (n = 37)
Clinical characteristic Number of
patients (%)
Sex
Men 18 (49)
Women 19 (51)
Age (years)
Median (range) 58 (31 to 79)
Race
White 26 (70)
African-American 8 (22)
Asian 3 (8)
No. of prior therapies
Median (range) 4 (1 to 10)
Time from diagnosis to the first cycle (months)
Median (range) 35.5 (4 to 121)
ECOG
0 4 (11)
1 33 (89)
RMH score
0 to 1 28 (76)
2 to 3 9 (24)
Tumor types
CRC 23 (62)
Gynecological 4 (11)
Lung 4 (11)
Head and neck 3 (8)
Othera 3 (8)
ECOG, Eastern Cooperative Oncology Group; RMH, Royal Mandersen Hospital;
CRC, colorectal cancer. aCholangiocarcinoma (n = 1), breast cancer (n = 1), and
esophageal cancer (n = 1).
Table 2 Dose escalation cohort and distribution of
patients (n = 37)
Dose level Number of
patients treated
Azacitidine
(mg/m2)
Oxaliplatin IV
(mg/m2/day)
DLT
1 3 20 15 0
2 3 20 22.5 0
3 3 20 30 0
4 3 25 30 0
5 3 40 30 0
6 6 50 30 0
Expansion
(dose level 6)
16 50 30 0
DLT, dose-limiting toxicity.
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Overall, no DLT was reported. Adverse events are
summarized in Table 3. Twenty-eight (76%) patients
developed adverse events > grade 1. The most common
non-hematological adverse events were fatigue (n = 17,
46%), nausea (n = 13, 35%), and vomiting (n = 12, 32%);
the most common hematological events were anemia
(n = 18, 49%) and thrombocytopenia (n = 15, 41%). No
grade 4 or 5 adverse events were reported. Overall, 21
grade 3 adverse events were noted in 14 (38%) patients.
The most common grade 3 adverse events were anemia
(n = 4, 11%) and nausea (n = 4, 11%). Peripheral neur-
opathy was noted in six patients (16%) (grade 1, n = 5;
grade 2, n = 1).Pharmacokinetics and platinum concentration
The plasma concentrations of oxaliplatin and azacitidine
are summarized in Figure 1a,b. Briefly, the concentration
of both oxaliplatin and azacitidine dropped rapidly afterTable 3 Summary of adverse events at least possibly
related to the treatment reported by ≥10% of patients
overall (safety population)
Toxicity Grade 1 Grade 2 Grade 3 Total
(%)
Non-hematological
Fatigue 5 10 2 17 (46)
Nausea 9 1 4 13 (35)
Vomiting 5 4 3 12 (32)
Constipation 4 5 9 (24)
Hyponatremia 4 3 7 (19)
Hypomagnesemia 7 7 (19)
Hypokalemia 4 2 1 7 (19)
Hypocalcemia 5 2 7 (19)
Peripheral neuropathy 5 1 6 (16)
Creatinine increase 4 2 6 (16)
Alkaline phosphatase increase 2 4 6 (16)
Dyspnea 5 5 (14)
Elevated AST/ALT 2 2 1 5 (14)
Hypoalbuminemia 3 1 4 (11)
Hyperkalemia 3 1 4 (11)
Diarrhea 4 4 (11)
Hematological
Anemia 2 12 4 18 (49)
Thrombocytopenia 13 2 15 (41)
Leukopenia 6 4 10 (27)
Lymphocytopenia 3 3 2 8 (22)
Neutropenia 4 1 1 6 (16)
Figure 1 Plasma concentrations of oxaliplatin and azacitidine. (a) Pharmacokinetic results for oxaliplatin. (b) Pharmacokinetic results for azacitidine.
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demonstrated a negligible difference between treatment
days 1 and 5 at any dose level.
The pharmacokinetic data for all dose levels of oxali-
platin are summarized in Table 4. At the maximum
dose level tested, the oxaliplatin Cmax was 650 ng/ml,
the t1/2 was 16.5 h, the clearance was 24.5 l/h/m
2, the
volume of distribution was 554 l/m2, and the AUC0-inf
was 1,456 h-ng/ml.
The pharmacokinetic data for all dose levels of azaciti-
dine are also summarized in Table 5. On days 1 and 5, at
the maximum dose level tested, the azacitidine Cmax was581 and 638 ng/ml, the t1/2 was 0.67 and 0.42 h, the
clearance was 178 and 156 l/h/m2, the volume of distri-
bution was 121 and 94 l/m2, and the AUC0-inf was 412
and 432 h-ng/ml, respectively.
Total platinum levels in snap-frozen tumor samples
were determined pre- and post-treatment in seven pa-
tients treated in the expansion phase. The pre-dose plat-
inum levels ranged from <0.25 to 5.8 μg/g tumor
(median, 0.59). The platinum concentration increased 3-
to 18-fold (median, 3.8-fold) in five post-dose tumor
samples, but it remained unchanged in the two tumor
samples with the highest pre-dose level.
Table 4 Mean (± SD) pharmacokinetic parameter estimates for oxaliplatin (day 2) using non-compartmental analysis
Oxaliplatin (mg/m2) 20/15 (n = 3) 20/22.5 (n = 3) 20/30 (n = 3) 25/30 (n = 3) 40/30 (n = 3) 50/30 (n = 22)
Visit C1D2 C1D2 C1D2 C1D2 C1D2 C1D2
AUCall (h-ng/ml) 704.3 (228.5) 1,178.4 (238.0) 1,149.0 (930.3) 1,369.1 (556.1) 1,543.5 (502.1) 1,286.3 (627.0)
AUCinf (h-ng/ml) 1,003.5 (211.1) 1,359.3 (167.1) 1,411.6 (1,065.1) 1,919.4 (923.3) 1,867.0 (387.0) 1,455.9 (657.6)
Cmax (ng/ml) 337.3 (141.3) 573.5 (131.1) 446.9 (447.8) 582.6 (270.3) 751.7 (275.5) 649.4 (384.5)
t1/2 (h) 38.9 (31.9) 17.9 (7.7) 18.6 (11.9) 23.7 (10.2) 23.3 (15.6) 16.5 (7.1)
CL (l/h/m2) 15.5 (3.7) 16.7 (2.0) 29.1 (15.7) 19.2 (11.4) 16.6 (3.9) 24.5 (10.2)
Vd (l/m
2) 829.2 (580.0) 443.5 (232.2) 794.5 (703.8) 587.5 (240.1) 613.8 (541.2) 554.0 (250.7)
Cmax, maximum concentration; AUC, area under the curve; t1/2, half-life of elimination; Vd, volume of distribution; CL, clearance.
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Methylation studies were done using specimens from
patients treated in the expansion phase. Overall, 15 biopsy
samples from 8 patients were available for methylation
studies. Three of these specimens were necrotic and one
specimen had no tumor cells identified. Paired compari-
son of methylation studies (post- vs. pre-treatment) in
tumor tissues was possible in seven patients. Paired com-
parison of methylation studies (post- vs. pre-treatment) in
blood was possible in nine patients. All blood samples
showed reduction in global DNA methylation from pre-
to post-treatment (median, −22%; range, −32%, −12%)
(Figure 2a). However, tumor samples showed mixed
DNA methylation response to treatment (median, −8%;
range, −34%, +33%), with a mean difference of −21.8
(95% confidence interval (CI) [18] = −26.4, −17.1; P <
0.0001; Figure 2b). Overall, four out of seven patients
showed evidence of demethylation in the tumor. For
example, one patient had a reduction in global tumor
DNA methylation of −34%, but another patient had an
increase in global tumor DNA methylation of +33%
post-treatment. No significant correlation was seen be-
tween methylation changes and tumor tissue platinum
content, and there was no correlation between demeth-
ylation in blood and demethylation in tumor tissues.
CTR1 scores and Ki-67
Of 15 available tissue specimens (expansion phase), 5 were
not evaluable for CTR1 score and Ki-67 assessment be-
cause of the absence of tumor cells. Paired comparison of
CTR1 scores and Ki-67 levels (post- vs. pre-treatment)
was available in four patients. The cytoplasmic and nu-
clear CTR1 scores pre- and post-treatment are summa-
rized in Figure 2c,d. Briefly, the mean pre-treatment
and post-treatment cytoplasmic CTR1 scores were
217.5 (range, 160 to 270) and 177.5 (range, 100 to 240),
respectively, which represent a statistically significant de-
crease of −40 (95% CI: −69.1, −10.9; P = 0.022). There was
also a decrease in the mean nuclear CTR1 score from
pre- to post-treatment; however, it did not reach statistical
significance (67.5 vs. 42.5 (−25.0; 95% CI: −55.5, +5.5; P =
0.08)). The average Ki-67 levels were 77.5% and 76% pre-and post-treatment, respectively. No significant correl-
ation was seen between CTR1 scores, methylation studies,
and tumor tissue platinum content. However, there was a
borderline correlation between the nuclear CTR1 score
and the Ki-67 changes (P = 0.05).
Antitumor activity
Overall, 36 (97%) patients had response assessment after
two cycles, and 13 (36%) patients had stable disease. No
objective response (complete remission or partial remis-
sion) was noted. Two patients had stable disease for six
cycles. The characteristics of patients with stable disease
are summarized in Additional file 1: Table S1. The mean
progression-free survival (PFS) duration was 2.5 months
(range, 1 to 6). There was no evident correlation be-
tween PFS and the CTR1 scores. There was a trend to-
ward correlation between the change in oxaliplatin
content and PFS (Spearman r = 0.71, P = 0.07).
Discussion
This phase I clinical trial evaluated the safety, pharmaco-
kinetics, and pharmacodynamics of oxaliplatin and aza-
citidine combination therapy in patients with advanced
cancer relapsed/refractory to prior platinum therapy. Pa-
tients had advanced-stage disease and were heavily pre-
treated (median number of prior therapies, 4). Overall,
this regimen was very well tolerated. The most common
grade 3 adverse events (fatigue, cytopenia, nausea) were
expected given the adverse events previously reported
with each drug separately. Surprisingly, in the current
study, the incidence of peripheral neuropathy was very
low (16%, all grade 1 to 2; no patient had neuropathy ≥
grade 3). Other investigators have reported a high inci-
dence of peripheral neuropathy with oxaliplatin treatment
(40% to 50% for all grades; 10% to 20% for grade ≥3) [28].
The lower incidence of peripheral neuropathy in our
study may be attributed to the divided dose of oxalipla-
tin given over 4 days compared to a higher dose given
once every 2 to 3 weeks. The use of this oxaliplatin regi-
men was based on our design of the OFAR (oxaliplatin,
fludarabine, ara-C, rituximab) regimen for patients with ag-
gressive chronic lymphocytic leukemia/Richter syndrome
Table 5 Mean (± SD) pharmacokinetic parameter estimates for azacitidine (days 1 and 5) using non-compartmental analysis
Azacitidine (mg/m2) 20/15 (n = 3) 20/22.5 (n = 3) 20/30 (n = 3) 25/30 (n = 3) 40/30 (n = 3) 50/30 (n = 22)
Visit C1D1 C1D5 C1D1 C1D5 C1D1 C1D5 C1D1 C1D5 C1D1 C1D5 C1D1 C1D5
AUCall (h-ng/ml) 216.4 (157.1) 193.1 (108.2) 428.1 (364.0) 317.1 (90.7) 112.5 (118.8) 143.7 (46.8) 210.1 (149.7) 207.7 (146.0) 97.5 (66.7) 205.9 (128.8) 404.5 (191.5) 426.5 (262.5)
AUCinf (h-ng/ml) 220.7 (157.6) 196.0 (108.7) 2,328.0 (3,647.5)
a 356.6 (147.7) 125.3 (108.1) 145.5 (47.1) 216.1 (147.2) 214.3 (144.8) 100.5 (67.1) 211.8 (131.8) 412.1 (195.7) 431.5 (261.7)
Cmax (ng/ml) 327.0 (258.8) 333.5 (84.0) 427.2 (223.8) 452.4 (214.3) 206.5 (208.6) 214.1 (61.5) 251.9 (116.1) 273.2 (132.0) 189.6 (122.2) 289.0 (138.1) 581.1 (284.8) 637.7 (428.6)
t1/2 (h) 0.54 (0.37) 0.35 (0.18) 10.89 (18.25) 1.27 (1.45) 0.54 (0.44) 0.34 (0.04) 0.33 (0.15) 0.72 (0.37) 0.16 (0.07) 0.27 (0.04) 0.67 (1.03) 0.42 (0.09)
CL (l/h/m2) 167.1 (170.5) 136.7 (97.0) 62.7 (53.9) 62.9 (25.4) 239.3 (139.2) 146.1 (40.0) 168.6 (126.7) 150.0 (74.6) 616.6 (525.5) 253.0 (165.5) 177.7 (155.9) 156.2 (80.7)
Vd (l/m
2) 92.3 (58.9) 61.1 (35.4) 78.6 (54.4) 85.4 (69.0) 226.5 (253.4) 71.6 (19.0) 70.3 (35.7) 132.2 (62.5) 105.8 (37.0) 95.6 (57.3) 120.6 (112.0) 94.0 (50.7)
aMedian = 259.2. Cmax, maximum concentration; AUC, area under the curve; t1/2, half-life of elimination; Vd, volume of distribution; CL, clearance.
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Figure 2 Methylation changes and cytoplasmic and nuclear CTR1 scores pre- and post-treatment. (a) Demethylation changes in blood.
(b) Demethylation changes in tumor. (c) Cytoplasmic CTR1 score changes in tumor. (d) Nuclear CTR1 score changes in tumor.
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2 neuropathy was 8% (4 of 50 patients) and no grade 3 to
4 neuropathy was noted. These protocols followed the ex-
ample of the prolonged infusion of anthracyclines, which
was associated with less cardiotoxicity compared to their
bolus administration [30-32]. Whether this oxaliplatininfusion regimen, which seems to have a better toxicity
profile, could affect the efficacy of the treatment needs
further investigation.
The pharmacokinetic data for oxaliplatin showed first-
order kinetics of elimination. Compared to traditional
infusion (once every 2 to 3 weeks) [33], the current
Tsimberidou et al. Clinical Epigenetics  (2015) 7:29 Page 8 of 11infusion regimen of oxaliplatin was associated with
lower Cmax (mean, 557 vs. 877 ng/ml) and lower AUCinf
(mean, 1,503 vs. 9,907 ng-h/ml) values. The major rea-
son for the AUC and Cmax difference is mainly due to
the relative lower single dose. It is possible that the
neurotoxicity may have been related to decreased peak
drug concentrations. Similarly, the pharmacokinetics of
azacitidine showed first-order kinetics of elimination,
and these data were similar on day 1 (prior to oxaliplatin
administration) and day 5 (after oxaliplatin administra-
tion), suggesting that oxaliplatin did not interfere with
the metabolism of azacitidine and that there was no self-
induction of azacitidine metabolism.
The mean systemic exposure of oxaliplatin (day 2) and
azacitidine (days 1 and 5) based on plasma AUCall values
resulted in a dose-dependent trend. Although when the
same dose of oxaliplatin was combined with increasing
doses of azacitidine (from 25 to 50 mg/m2), a reduction
in mean oxaliplatin exposure was observed, no signifi-
cant differences in the other non-compartmental mod-
eled parameters estimated were observed.
In the current study, hypomethylation was universal in
the peripheral blood samples of patients, but it was not
consistently observed in patients’ tumor tissues, as also
seen in a previous study using decitabine in solid tumors
[14]. The observed lack of demethylation has two pos-
sible explanations. First, azacitidine-induced DNA de-
methylation requires incorporation into DNA and thus
is limited to cells in S phase. Given the short half-life of
the drug, tumors with a low proliferation index might
not show much demethylation. Second, clonal shifts
confound DNA methylation analysis in tumors. Some
cancers have profound loss of LINE1 methylation at
baseline [34]. If the post-treatment biopsy contains fewer
tumor cells and more normal cells than the pre-
treatment biopsy, the apparent effect would be gain of
LINE1 methylation, as observed here in some patients.
Despite this caveat, the overall net effect was consistent
with demethylation after azacitidine exposure.
The hypomethylating agent decitabine has previously
been shown as a single agent to decrease DNA methyla-
tion and augment CTR1 expression in tumors with ini-
tially low CTR1 expression (immunohistochemistry (IHC)
score <150) [14]. In our study, no patient had a baseline
IHC score <150 (mean, 217.5; range, 160 to 270). It has
been shown that the use of a platinum compound de-
creases CTR1 expression [12] and causes secondary plat-
inum resistance [35]. It is unknown how oxaliplatin alone
would have impacted CTR1 expression in our patients. It
will require additional testing to assess whether decrease
in CTR1 expression would have been much greater with
oxaliplatin alone, with some mitigation by azacitidine of
the impact of oxaliplatin. Whether higher doses of azaciti-
dine would increase CTR1 expression needs furtherinvestigation; however, the effect of the dose was not seen
with decitabine. Furthermore, no correlation was noted
between the methylation status and CTR1 expression,
which is in line with previously reported data on decita-
bine showing that CTR1 expression was mediated by
methylation-independent mechanisms [14].
The clinical application of CTR1 expression and re-
sponse to platinum agents is still evolving. In patients
with non-small cell lung cancer treated with neo-
adjuvant platinum-based chemotherapy, higher CTR1
expression was associated with better response to plat-
inum compounds, but the intensity of CTR1 expression
did not correlate with tumor tissue platinum concentra-
tion [36]. These findings are compatible with our obser-
vation that changes in tumor platinum concentration
were not correlated with changes in CTR1 expression
and that higher tumor platinum concentrations (com-
pared to baseline) were associated with a trend toward
longer PFS (P = 0.07).
Conclusions
The combination of continuous-infusion oxaliplatin (days
1 to 5) and azacitidine (days 2 to 5) had a very safe toxicity
profile. The most common adverse events were anemia
and fatigue. Two of 37 (5.4%) heavily pre-treated patients
had stable disease and completed six cycles of therapy.
Oxaliplatin (D2) and azacitidine (D1 and 5) mean systemic
exposure based on plasma AUCall showed dose-dependent
interaction whereby increasing the dose of oxaliplatin re-
duced the mean azacitidine exposure and vice versa. Blood
samples showed universal reduction in global DNA
methylation. In tumor samples, hypomethylation was ob-
served in four of seven patients. No correlation between
blood and tumor demethylation was seen. The mean cyto-
plasmic CTR1 score decreased. The pre-dose tumor oxali-
platin levels ranged from <0.25 to 5.8 μg/g tumor. The
platinum concentration increased 3- to 18-fold. Further
studies with higher doses, different schedules of azaciti-
dine and oxaliplatin, and control arm of single-agent oxa-
liplatin would provide additional information regarding
the effect of azacitidine on global methylation and CTR1
expression and their association with clinical outcomes.
Methods
Patient eligibility
Eligible patients had a histologically confirmed advanced
malignancy that was metastatic or unresectable and for
which standard curative or palliative measures were not
expected to increase survival by at least 3 months. In
addition, the patients’ cancers were relapsed or refractory
to any platinum compound. Platinum-refractory disease
was defined as disease that did not respond to a plat-
inum compound-containing regimen or that recurred
after treatment with a platinum compound-containing
Tsimberidou et al. Clinical Epigenetics  (2015) 7:29 Page 9 of 11regimen. At least one prior chemotherapy regimen was
required, and patients had to be ≥6 weeks beyond treat-
ment with a nitrosourea compound or mitomycin-C
and ≥4 weeks beyond any other chemotherapy or radio-
therapy and recovered to ≤ grade 1 toxicity after any
treatment-limiting toxicity of prior therapy. Patients
were required to have acceptable clinical functions, in-
cluding an Eastern Cooperative Oncology Group perform-
ance status ≤2 (Karnofsky score >60%) and normal organ
and marrow functions, as defined by leukocytes ≥4,000/μl,
absolute neutrophil count ≥1,500/μl, platelets ≥100,000/μl,
total bilirubin ≤1.0 mg/dl, aspartate transaminase/alanine
transaminase ≤3× the institutional upper limit of normal,
serum creatinine ≤2.0 mg/dl, and international normalized
ratio (INR) ≤1.75 (per institutional guideline). All male
and female subjects of childbearing potential were edu-
cated about practicing effective contraception during the
study and were willing and able to continue contraception
for 3 months after their last dose of study treatment.
All patients provided written informed consent, stat-
ing that they were aware of the experimental nature of
the study. This clinical trial was conducted with the ap-
proval of and in accordance with the guidelines of The
University of Texas MD Anderson Cancer Center Insti-
tutional Review Board and The Cancer Therapy Evalu-
ation Program at the National Cancer Institute (www.
clinicaltrials.gov, NCT01039155).
Treatment planning
In the dose escalation phase, patients were treated with
azacitidine at 20 to 50 mg/m2/day intravenously (IV)
over 15 to 30 min on days 1 to 5 and with oxaliplatin at
15 to 30 mg/m2/day IV over 2 h on days 2 to 5 (six dose
levels; Table 2). This phase was followed by an expan-
sion phase in which patients with CRC were treated with
the maximum tolerated dose (MTD). Patients were
treated with six cycles of therapy, unless they withdrew
consent or experienced severe adverse events or progres-
sive disease.
Pharmacokinetics
The pharmacokinetics of azacitidine was assessed during
cycle 1 (days 1 and 5) to permit correlation of pharma-
cokinetic parameters with hypomethylation effects.
Blood samples (10 ml per sample) were to be collected
at the following time points: immediately prior to azaci-
tidine infusion, immediately after infusion, and at 5, 10,
15, 30, 60, and 90 min and 2, 3, and 6 h after infusion.
Samples were assayed for azacitidine using an ultra-
performance liquid chromatography/electrospray mass
spectrometry method following isolation of the drug
from plasma. Compartmental and non-compartmental
modeling were used to derive pharmacokinetic parame-
ters, including Cmax (maximum concentration), AUC(area under the curve), t1/2 (half-life of elimination), Vd
(volume of distribution), and CL (clearance).
Oxaliplatin pharmacokinetics were assessed on day 2
during cycle 1 to permit correlation of pharmacokinetic
parameters with toxicity and treatment outcome. Blood
samples (10 ml per sample) were collected immediately
prior to oxaliplatin infusion, immediately after infusion,
and at 1, 2, 4, 6, 8, 12, and 24 h after infusion. Samples
were assayed for total and unbound platinum using ei-
ther inductively coupled plasma mass spectrometry or
atomic absorption spectroscopy methods following iso-
lation of the drug from plasma. Compartmental and
non-compartmental models were used to derive phar-
macokinetic parameters, including Cmax, AUC, t1/2, Vd,
and CL.
Pharmacodynamics
Tumor core biopsies were performed within 2 weeks be-
fore starting azacitidine and on day 12 (±1 day) of cycle
1 in the expansion phase.
Measurement of oxaliplatin levels in tissue
The tumor tissue was frozen and stored in cryogenic stor-
age tubes before being analyzed for total platinum content
using inductively coupled plasma mass spectrometry. If a
sufficient amount of the sample remained following this
analysis, the tissue was subjected to homogenization and
extraction with 0.2% formic acid and acetonitrile for ana-
lysis by ultra-performance liquid chromatography/mass
spectrometry for oxaliplatin content.
Measurement of DNA methylation
DNA was extracted and treated with bisulfite. A LINE1
assay [37] coupled with pyrosequencing [38] was used to
determine global DNA methylation.
Immunohistochemical analysis
Five-micrometer-thick formalin-fixed and paraffin-embed-
ded tumor tissue sections were deparaffinized and hy-
drated. Sections were stained using mouse antibodies for
CTR1 (polyclonal; dilution 1:400; 90 min of incubation at
room temperature; GeneTex Inc., San Antonio, TX, USA)
and Ki-67 (monoclonal, clone MIB1; dilution 1:200;
90 min of incubation at room temperature; Dako Inc.,
Carpinteria, CA, USA). Cytoplasmic CTR1 was quantified
using a four-value intensity score (0 to 3+). The cytoplas-
mic expression score (range, 0 to 300) was obtained by
multiplying the intensity score and the percentage of
tumor cell staining. Nuclear CTR1 and Ki-67 expressions
were reported as the percentage of positive nuclei among
tumor cells assessed. Changes in these scores and in the
number of mitoses per high-power field, percentage of ne-
crosis, were calculated by subtracting values at baseline
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lation of percent changes.)
Statistical considerations
A ‘3 + 3’ dose escalation study design was used. The MTD
was defined as the highest dose at which six subjects were
treated with at most one subject experiencing a DLT. DLT
was defined as any toxicity ≥ grade 3 according to National
Cancer Institute Common Terminology Criteria for Ad-
verse Events, Version 4.0; ≥grade 3 nausea/vomiting and
diarrhea for >3 days despite supportive care; or febrile
neutropenia of any duration. An asymptomatic grade 3 in-
crease in aspartate transaminase, alanine transaminase,
lipase, or amylase levels lasting ≤7 days was not consid-
ered a DLT. Alopecia, grade 3 fatigue lasting ≤7 days, and
grade ≥3 thrombocytopenia or neutropenia lasting ≤7 days
were not considered DLTs. Once treatment-related toxic-
ities developed, the subsequent cycle was delayed until the
absolute neutrophil count was ≥1.0 × 109/l, the platelet
count was ≥100 × 109/l, and the treatment-limiting toxic
effect decreased to ≤ grade 1.
Tumor response was assessed using the Response Evalu-
ation Criteria in Solid Tumors, version 1.1. PFS was mea-
sured from the first day of treatment on the clinical trial
until the date of disease progression or death, which-
ever came first. Patients’ characteristics were analyzed
using descriptive statistics. Spearman rank was used to
analyze the correlation between demethylation change,
platinum content changes, CTR1 cytoplasmic and nu-
clear scores, Ki-67 percentage, and the time on study.
All P values presented are two-sided and statistical sig-
nificance means P ≤ 0.05.
Additional file
Additional file 1: Table S1. Characteristics of treated patients with
stable disease.
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